Inflammatory bowel diseases | 23 Feb 2013
A Sakuraba, K Keyashian, C Correia, J Melek, RD Cohen, SB Hanauer and DT Rubin
: Natalizumab is an efficacious agent for the induction and maintenance of remission in patients with Crohn’s disease (CD) who have failed anti-tumor necrosis factor (TNF) agents. We aimed to assess the efficacy and safety of natalizumab outside of clinical trial at a US tertiary center.
* Data courtesy of Altmetric.com